Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Fineline Cube Jan 12, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Company Deals

Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem

Fineline Cube Nov 21, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...

Company Drug

Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC

Fineline Cube Nov 21, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...

Company Drug

Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV

Fineline Cube Nov 21, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

Fineline Cube Nov 21, 2022

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...

Policy / Regulatory

Jiangxi Leads 22-Province Alliance in VBP for Liver Function Test Reagents

Fineline Cube Nov 21, 2022

The provincial drug and medical consumables centralized procurement joint meeting office of Jiangxi has released...

Company Deals

Fapon Biotech Partners with Roche Diagnostics at China International Import Expo

Fineline Cube Nov 18, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with Swiss major Roche Diagnostics at...

Company Medical Device

China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel

Fineline Cube Nov 18, 2022

The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life...

Company Drug

Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency

Fineline Cube Nov 18, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Deals

RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development

Fineline Cube Nov 18, 2022

China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of...

Company

Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth

Fineline Cube Nov 18, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its Q3 2022 financial report, recording...

Company Deals

Marinus Pharmaceuticals Collaborates with Tenacia Biotechnology for Ganaxolone

Fineline Cube Nov 18, 2022

Pennsylvania-based pharma company Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has entered into a collaboration and supply...

Company Legal / IP

Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation

Fineline Cube Nov 18, 2022

US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...

Legal / IP Policy / Regulatory

CDE Issues Trial Rules for NMPA Drug Review Timekeeping Suspension

Fineline Cube Nov 18, 2022

The Center for Drug Evaluation (CDE) has released the “NMPA Drug Review Timekeeping Suspension and...

Company Medical Device

Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...

Company Medical Device

Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan

Fineline Cube Nov 18, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...

Company Drug

BeiGene’s Brukinsa Receives EC Approval for CLL Treatment

Fineline Cube Nov 18, 2022

China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...

Company

Zhangjiang AI New Drug R&D Alliance Expands with New Members

Fineline Cube Nov 18, 2022

The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...

Company Deals

Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging

Fineline Cube Nov 17, 2022

Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...

Company Drug

Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs

Fineline Cube Nov 17, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...

Posts pagination

1 … 539 540 541 … 607

Recent updates

  • Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA
  • Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity
  • Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery
  • NHSA Launches Personal Healthcare Insurance Cloud Pilot Program
  • China Expands Medical Insurance Personal Account Pooling Nationwide
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA

Company

Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.